Candel Therapeutics Announces Pricing of Initial Public Offering
NEEDHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the pricing of its initial public offering of 9,000,000…
